A reduction in peripheral CD4+ cell levels has been correlated with the onset of Pneumocystis carinii pneumonia in AIDS patients. Most in vivo drug discovery and development for P. carinii have been conducted in corticosteroid-treated rats. There is need for the development of new small animal models with more selective methods of immunosuppression. This study outlines a new mouse model in which specific depletion of the CD4+ T-lymphocyte population was achieved by subcutaneous injection of GK1.5 hybridoma cells into C3HeB/FeJ mice. A significant reduction in splenic CD4+ cells was maintained over a 10-week period following a single injection of cells. Circulating anti-CD4+ antibody was detected throughout the 10-week period in hibridoma-injected mice, while circulating antibody was undetectable 4 weeks after repeated injection of purified monoclonal antibody. There was no significant increase in the CD8+ cell populations of the hybridoma-injected mice. P. carinii cysts increased in the lungs of CD4+ T-cell-depleted mice, with the number of cysts detected comparable to levels in dexamethasone-treated mice. High levels of cysts were detected when CD4+ cell populations in the spleen remained below 5% and decreased when CD4+ populations increased above the 5% level. In mice whose CD4+ population was not reduced below 5%, there was no significant increase in P. carinii cysts detected. This study presents a new mouse model with specific immunosuppression requiring a minimum of animal manipulation for use in discovery and development of potential new therapeutics for P. carinii pneumonia.
CD4+ cell populations in the spleen remained below 5% and decreased when CD4+ populations increased above the 5% level. In mice whose CD4+ population was not reduced below 5%, there was no significant increase in P. carinii cysts detected. This study presents a new mouse model with specific immunosuppression requiring a minimum of animal manipulation for use in discovery and development of potential new therapeutics for P. carinii pneumonia.
Pneumocystis carinii is an opportunistic pathogen that causes a fatal pneumonia in immunocompromised patients if left untreated. It is characterized by the presence of P. carinii organisms and an eosinophilic infiltrate within the lung alveoli. The incidence of P. carinii pneumonia (PCP) has become more common as a result of the AIDS epidemic, and it has been found that there is a correlation between peripheral CD4+ T-lymphocyte levels in AIDS patients and the onset of PCP (15) . As a result, CD4+ T-cell levels are monitored in patients diagnosed as human immunodeficiency virus positive to determine whether they are at risk of developing PCP. In most cases, patients with CD4+ levels below 200/mm3 are put onto prophylactic regimens (21) . Since agents currently used to treat and prevent PCP have a high incidence of adverse reactions, especially in AIDS patients, new chemotherapeutics with improved safety and efficacy are still needed. Animal models are required for the discovery and development of these potential new therapeutics.
In vitro propagation of P. carinii has proven difficult, and most research has been conducted in vivo, largely in corticosteroid-treated rats. While this model has proven reliable and predictive of drug efficacy in humans (12, 13) , it depends on the use of nonspecific immunosuppressants and often requires large quantities of test compound, which in many cases is restrictive in the early stages of drug discovery. A mouse model for PCP would offer advantages over the rat model, since much less test compound would be needed and more animals could be included in test groups. In addition, the variety of inbred mouse strains currently available would provide opportunities to conduct epidemiological and immunological studies which cannot be achieved in the rat.
Initial studies undertaken by Walzer et al. (24) , conducted with various strains of chemically immunosuppressed mice, found the level of P. carinii infection highly variable. More recent models achieve consistent and predictable P. carinii infections by inoculating mice with infected lung tissue (2, 8, 25) or through cohabitation with P. carinii-infected mice (16) . However, these models still require immunosuppression with corticosteroids. This nonspecific immunosuppression predisposes animals to a high incidence of other opportunistic infections and may have metabolic side effects, resulting in a reduction in survival time. In addition, it is likely that corticosteroids also limit the extent of pneumonia as a result of their anti-inflammatory effects, and therefore these models may not be true representations of PCP. The use of corticosteroids to overcome respiratory distress in patients with acute PCP has been reported (22) .
An alternative approach to corticosteroid immunosuppression is to selectively deplete mice of CD4+ T cells. The first indications that T cells were involved in the development of PCP in mice became apparent when spontaneous PCP outbreaks occurred in severe combined immunodeficiency and athymic mouse colonies (17, 18, 20, 23) . Specific evidence of CD4+ cell involvement in host defense against P. carinii was supported by studies in which an anti-mouse CD4+ monoclonal antibody (MAb) was injected weekly to passively deplete CD4+ cells, resulting in P. carinii infections (19 were removed and teased apart by using the frosted end of glass microscope slides in 3 ml of PBS (Gibco, Grand Island, N.Y.). Cells were centrifuged for 5 min at 400 x g. The supernatant was decanted and cells were resuspended in 1 ml of ACK lysing buffer (Gibco) to lyse erythrocytes, diluted in 3 ml of PBS, and centrifuged for 5 min at 400 x g. Cells were resuspended in 1 ml of PBS, and 100 ,ul was either double stained with 10 ,ul (containing 1 ,ug) of fluorescein isothiocyanate-conjugated L3T4+ (CD4+) MAb (PharMingen, San Diego, Calif.) and 10 RI (containing 1 ,ug) of R-phycoerythrinconjugated Lyt-2+ (CD8a+) MAb (PharMingen) or single stained with 10 ,lI (containing 1 ,ug) of fluorescein isothiocyanate-conjugated Thy 1.2+ MAb (PharMingen). The cells and labeled antibody were incubated for 30 min at room temperature. Samples were diluted with 3 ml of PBS and centrifuged at 400 x g for 5 min. The supernatant was decanted and cells were resuspended in 200 ,lI of propidium iodide (1 ,ug/ml; Sigma). Samples were analyzed on a FACScan analyzer (Becton Dickinson, San Jose, Calif.).
P. carinii cyst determination. Lungs from mice were excised, and the number of P. carindi cysts per lung was determined as previously described (16 of circulating rat antibody over time (Table 1) . One week after the injection of cells, the amount of circulating antibody (38.90 ± 6.12 ng/ml) was lower than in the mice that received the injection of purified MAb (55.09 ± 2.06 ng/ml). However, by week 2 the GK1.5 hybridoma cell-injected group had levels of circulating rat antibody similar to those measured in the sera of mice that had received both doses of MAb (80.27 ± 15.53 ng/ml in the hybridoma mice compared with 76.76 ± 4.86 ng/ml in the antibody-treated mice). By week 3, antibody levels in the 5 x 106 GK1.5 cell group continued to increase (123.37 ± 56.30 ng/ml), while levels in the MAb-treated group had begun to decrease (20.05 ± 6.61 ng/ml). The variability in circulating rat antibody was greater in the 5 x 106 GK1.5 cell group than in the MAb-treated group, and at some time points only some of the mice had detectable antibody. Most animals with any level of rat antibody detected by ELISA had less than 1% CD4+ cells as measured by FACS analysis. The 4-and 6-week time points, when antibody was detected in only some of the mice, corresponded with increases in the CD4+ T cells (see Fig. 4 ), and at weeks 5 and 8 extremely high levels of antibody (>1,000 ng/ml), accompanied by reduced CD4+ splenic T-cell populations, were found. At week 10, a reduction in detectable antibody in the sera of mice (127.37 ± 61.17 ng/ml), accompanied by increasing CD4+ splenic T cells, was found.
MAb treatment. The administration of two injections of 0.5 mg of antibody 1 week apart rapidly decreased the level of CD4+ T cells in C3HeB/FeJ mice (Fig. 2) . Administration of purified antibody resulted in a significant (P < 0.001) reduction 1 week after the first injection, with less than 1% CD4+ cells detected in the spleens of all mice sampled. Nonantibody-treated C3HeB/FeJ mice had an average of 23% ± 1.29% CD4+ spleen cells. Thus, the MAb treatment depleted greater than 95% of the CD4+ cell population. Although all mice sampled up to week 4 of the study had less than 1% CD4+ cells, CD4+ cells gradually increased during the subsequent weeks of the study. The reduced CD4+ T-cell levels, while increasing, remained significantly (P < 0.001) depressed below normal levels throughout the entire study period.
The course of P. carinii infection was quantitated in conjunction with FACS analysis (Fig. 2) . While Injection of GK1.5 cells s.c. Injection of 107 GK1.5 hybridoma cells resulted in significant depletion of CD4+ cells in the spleen and detectable levels of P. carinii cysts in the lungs (Fig.  3) . The five mice sampled at week 1 had a mean of 0.2% ± 0.0% CD4+ T cells, a significant reduction (P < 0.001) from the normal level of 23% ± 1.29%. The percent CD4+ cells remained significantly reduced (P < 0.001) throughout the 10 weeks of study. The levels of CD4+ spleen cells remained below 1% through week 5 of the study but gradually increased during the later time periods. By week 10, the mice still had significantly reduced CD4+ cell levels (7.4% ± 1.7%).
P. carinii cysts were not detected in the lungs of mice until 3 weeks after the cells were injected (log mean, 3.99 + 0.31) (Fig. 3) . From weeks 3 to 8, the level of P. carinii cysts increased to a peak log mean value of 5.37 ± 0.29. The log mean number of cysts at week 10 (log mean, 4.97 ± 0.43) had decreased, though not significantly, compared with the levels of infectivity measured at the 6 (log mean, 5.35 + 0.34)-and 8 (log mean, 5.12 ± 0.29)-week time points.
Injection of 5 x 106 GK1.5 hybridoma cells s.c. resulted in significant depletion of CD4+ cells in the spleen and detectable levels of P. carinii cysts in the lungs (Fig. 4) . This level of hybridoma cells significantly reduced (P < 0.001) the CD4+ population to 0.2% ± 0.0% 1 week following injection. The percent CD4+ cells remained undetectable until week 4, when they rose to 3.0% ± 1.7%, still significantly reduced (P < 0.001) from controls; however, the CD4+ cells were again completely undetectable in the spleens by week 5. This fluctuation in percent CD4+ cells continued throughout the study, with a rise in the level at week 6 (3.8% ± 1.9%), reduction in week 8 (0.2% ± 0.1%), and a third rise in the splenic CD4+ population at week 10 (2.6% ± 2.4%). CD4+ levels in the spleen were significantly reduced (P < 0.001), compared with controls, at all time periods tested and levels did not rise above 4% throughout the 10-week study period.
P. carinii cysts were detected by week 3 (log mean, 4.02 0.17) and steadily increased over time (Fig. 4) , with maximum numbers of cysts detected 8 weeks (log mean, 5.96 ± 0.03) after the injection of hybridoma cells. Tissue load at 8 weeks in this group was greater than the peak cyst load measured in any of the other experimental groups, except in the dexamethasone-treated group (log mean, 5.91 + 0.13), in which the peak cyst load was similar. A slight decrease from the 8-week level was measured at 10 weeks (log mean, 5.46 ± 0.36) but still represented a significant infection. The level of P. carinii cysts in this group was more variable over time than in the 107 hybridoma cell group. P. carinii cyst levels corresponded with fluctuations observed in the CD4+ T-cell population. The CD4+ T-cell population in the spleens of mice injected s.c. with 106 GK1.5 cells was only partially decreased (Fig. 5 ) but still represented a significant reduction (P < 0.01) from controls at all time points. One week after injection, mice had a mean CD4+ spleen cell count of 5.2% ± 1.5%. The CD4+ cells remained between 5 and 10% through week 5 of the study and gradually began to approach normal levels by week 10 (18.7% ± 0.8%). The CD4+ spleen cell population did not fall below 5% at any time point during the study period. P. carinii infection occ cells (Fig. 5) on August 28, 2017 by guest http://iai.asm.org/ Downloaded from above 5% at 10 weeks after injection along with a concomitant decrease in P. carinii cysts.
In this model, we were able to selectively deplete CD4+ cells from immune competent mice without the use of broadspectrum immunosuppressants or frequent injection of antibody. The level of P. carinii infection achieved was similar to that attained by dexamethasone treatment. This represents a novel mouse model which more closely mimics the immunological predisposition of human immunodeficiency virus-positive patients at risk of developing PCP.
